Magnetic-anchor-guided endoscopic submucosal dissection shows promise for gastric cancerJanuary 28, 2009A prospective clinical trial from researchers in Japan shows magnetic-anchor-guided endoscopic submucosal dissection for large early gastric cancer to be a feasible and safe method in humans. Endoscopic submucosal dissection (ESD) is useful in the en bloc removal (in a single large piece) of large gastric lesions because it reduces the risk of a local recurrence caused by removing the lesions piecemeal (in multiple small pieces). ESD is a complicated procedure that requires a high level of skill by the endoscopist. The magnetic-anchor-guided endoscopic submucosal dissection (MAG-ESD) technique was developed to facilitate the standard ESD procedure. The researchers note that to their knowledge, this is the first clinical trial to use MAG-ESD for early gastric cancer in humans. The study appears in the January issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE). Endoscopy is a procedure that uses an endoscope -- a thin, flexible tube with a light and a lens on the end to look into the esophagus, stomach, duodenum, small intestine, colon, or rectum, in order to diagnose or treat a condition. There are many types of endoscopy, including colonoscopy, sigmoidoscopy, gastroscopy, enteroscopy, and esophogogastroduodenoscopy (EGD). Endoscopy allows direct visualization of the inner most lining of the gastrointestinal tract. This inner lining is called the mucosa. Many cancers originate from the mucosa of the gastrointestinal tract. Some examples include colon, esophageal and gastric (stomach) cancer. Precancerous changes and early stage cancers can be removed through an endoscope provided the cancer has not spread beyond the surface layers of the gastrointestinal lining. An important technique in removing these lesions is endoscopic mucosal resection (EMR). In this technique, a needle is passed through the endoscope and a liquid solution is injected under the area of interest, in effect "lifting" the abnormal tissue and separating it from the deeper intestinal layers. The abnormal lesion is then removed ("resected") with a snare; the tissue is subsequently retrieved through the endoscope and examined under a microscope. ESD is a specific EMR technique where a lesion, generally larger than what can be removed by standard EMR, is separated from the deeper layers of the intestinal wall under direct vision of the endoscopist. The endoscopist utilizes an electrocautery device to dissect the lesion (overlying the device) from the deeper intestinal layers (below the device). Unlike conventional surgery, where structures in the abdomen are readily able to be shifted (retracted) allowing better visualization, there is no good method to provide retraction when using the endoscope in ESD. MAG-ESD, controlled by an extracorporeal electromagnet, facilitates the standard ESD procedure by providing this retraction capability using magnets. According to the researchers, the MAG-ESD technique allowed for excellent visualization of the submucosal layer because it made suitable tissue tension possible. This simplifies a gastric ESD, even for large lesions in the gastric body. The study showed that the long-term exposure to the magnetic field did not cause any unwanted physiological or mental effects. Furthermore, no delayed complications or allergies related to the stainless steel magnetic anchor were observed. All the tumors were resected en bloc, without any perforation or severe uncontrollable bleeding. Patients and Methods The purpose of this prospective single center clinical trial was to evaluate the feasibility of MAG-ESD for large early gastric cancer in humans. The technique had previously been reported as successful in a porcine model. Twenty-five patients, median age 70 years, with early gastric cancer measuring > 20 mm located in the gastric body (stomach) were seen on an inpatient basis for an ESD at the National Cancer Center Hospital in Tokyo, Japan. The final aim was to achieve an en bloc resection (removal of the entire cancerous growth). The MAG system is composed of both internal and external components. The intracorporeal magnetic anchor consists of a hand-made stainless steel magnetic weight of six grams, and microforceps connected by a short thread. The magnetic anchor is delivered into the stomach of the patient through a hollow tube (overtube) that incorporates the endoscope and the magnetic weight. The extracorporeal magnetic control system includes a 35 cm extracorporeal magnet whose movement is controlled by the up-down motion of the external magnet itself as well as a movable examination table. The mobile examination table enabled control of the internal magnetic anchor so as to achieve ideal mucosal lifting to allow for the gastric submucosal dissection. The procedure began in standard ESD fashion with the injection of a liquid cushion into the submucosa and initial entry into the submucosa with the electrocautery device. The procedure was then carried out using the new MAG-ESD technique. The magnetic anchor was clipped to the free edge of the lesion in the stomach which can now be controlled by the large magnet outside the patient to provide an appropriate amount of tension. This makes it possible to peel back the portion of the lesion now separated from the submucosa, clearing the view of the endoscopist for safer removal of the lesion. After endoscopic resection, both the resected tissue and the magnetic anchor(s) were removed from the stomach. The demographic and clinical features of each patient were recorded in a case report form. Two gastrointestinal endoscopists assessed the data as to whether the magnetic anchor facilitated a gastric ESD, and was classified either "supportive" or "not supportive." The en bloc resection rate, complications, total operation time, bleeding, perforation and recurrence rate were also evaluated. Results The MAG-ESD technique was utilized in 25 patients. All tumors were resected en bloc (median size 5.5 cm), without any perforations or uncontrollable bleeding. All magnetic anchors were safely removed. The MAG system was evaluated as helpful in facilitation ESD in 23 of the 25 patients. In 21 patients, only one magnetic anchor was needed to achieve the desired result, either by rotating the patient or by moving the examination table. The MAG system effectively facilitated an ESD for all nine tumors located on the greater curvature of the gastric body. None of the patients experienced physiological or mental abnormalities as a result of magnetic field exposure either during the procedure itself or over the follow-up interval. No delayed adverse effects nor allergies were observed because of the stainless steel of the magnetic anchor. Eight weeks after an MAG-ESD, all artificial defects caused by ESD were completely healed. Neither recurrent cancer nor distant metastases were observed in any of the patients during follow-up. The study authors noted that the electromagnetic control system was cumbersome and advised that the system should be miniaturized to allow wider clinical application. While this human clinical trial demonstrated MAG-ESD's feasibility and safety, and offered excellent visualization due to suitable tissue tension, the researchers advised that further innovations are warranted to apply the MAG procedure in daily clinical practice. American Society for Gastrointestinal Endoscopy |
|||||||||||||||||||||
| Related Gastric Cancer Current Events and Gastric Cancer News Articles African-Americans with colorectal cancer have poorer outcomes, lower survival rates New research published in the November issue of the Journal of the American College of Surgeons shows that African-American patients with colorectal cancer are more likely to be diagnosed with advanced disease and are less likely to undergo surgical procedures compared with Caucasians, suggesting that improvements in screening and rates of operation may reduce differences in colorectal cancer outcomes for African-Americans. Is short-term Celecoxib intervention a effective method for preventing gastric carcinogenesis? Since the isolation and culture of Helicobacter pylori (H. pylori) in 1983, this bacterium has become accepted as an important human pathogen for the development of gastritis, peptic ulcer, and gastric cancer. A new explanation of 'Asian paradox' Although Helicobacter pylori (H. pylori) has been classified as a class I (or definite) carcinogen by World Health Organization (WHO), the controversy as to why only a minority of infected patients develop gastric cancer still remains. Will genomics help prevent the next pandemic? This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease. Protein interaction network can respond Helicobacter pylori infection? Helicobacter pylori (H pylori) is a gram negative bacterium which infects about 50% of the world population. H pylori colonization causes a strong systemic immune response. A case of post-gastrectomy acute pancreatitis Gastrectomy is commonly performed for both benign and malignant lesions. Although the incidence of post-gastrectomy acute pancreatitis (PGAP) is low compared to other well-recognized post-operative complications, it has been reported to be associated with a high mortality rate. Does Helicobacter pylori eradication therapy prevent gastric cancer? Although it has been demonstrated that Helicobacter pylori causes gastric cancer, it is still controversial that whether H. pylori eradication therapy is effective in primary prevention of gastric cancer. New blood tests promise simple, cost-effective diagnosis of gastrointestinal cancers Promising results from two new blood tests that can aid in the early identification of patients with gastrointestinal (GI) cancers will be presented at Europe's largest cancer congress. NIH study reveals new genetic culprit in deadly skin cancer Drawing on the power of DNA sequencing, National Institutes of Health researchers have identified a new group of genetic mutations involved in the deadliest form of skin cancer, melanoma. PPAR-g agonists have potential therapeutic role in gastric carcinoma? Recently, the potential of PPAR-γ as a target for the prevention and treatment of cancer has been widely studied. More Gastric Cancer Current Events and Gastric Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||